Galvanize believes the greatest opportunity for meaningful innovation lies where significant unmet clinical need affects large, underserved patient populations. We focus our technology and resources on diseases where existing treatment options leave too many patients without meaningful solutions, and where a fundamentally different approach has the potential to improve outcomes at scale.
We are working to bring forward solutions that impact large patient populations who face poor outcomes.
Only 15% of lung cancer cases are currently found in the early stages,
when the survival rate is 53.5%*
Most lung cancer cases aren’t diagnosed until later stages,
when the survival rate is only 3.9%*
Every 2.5 min someone is
diagnosed with lung cancer*
Lung cancer, along with breast cancer, is the most common cancer*
| Stage I | Stage II | Stage IIIA | Stage IIIB | Stage IV | |
|---|---|---|---|---|---|
| 5-year survival | 54% | 35% | 10-15% | <5% | <2% |
| Surgery | ● | ● | ● | ||
| Radiotherapy | ● | ● | ● | ● | ● |
| Chemotherapy | ● | ● | ● | ● | |
| Targeted therapy | ● | ||||
| Immunotherapy | ● | ● | ● | ● | ● |
| Focal ablation | ● | ● | |||
| Aliya® PEF | ● | ● | ● | ● | ● |
Currently investigating the use of Aliya PEF in conjunction with standard of care therapies to improve outcomes
With chronic bronchitis, the airways produce excess mucus, resulting in chronic cough and shortness of breath.
†Reference: CDC 2018. COPD Trends Brief – Prevalence | American Lung Association
Chronic bronchitis develops after exposure to cigarette smoke, vaping, secondhand smoke, airborne chemicals, or other pollution and irritants.
1
2
3
COPD patients with chronic bronchitis have a reduced quality of life, worse respiratory symptoms, and a higher risk of exacerbations compared to COPD patients without chronic bronchitis.
5-year mortality increases by nearly
30% with 3+ mucus plugs
64% worse
respiratory symptoms
1.4x more likely
to be awakened by cough
Currently treatment options for the symptoms of chronic bronchitis that directly target the cells that produce mucus are limited.
"*" indicates required fields
Galvanize Therapeutics® is a medical device manufacturer, not a healthcare provider. The information submitted through this form will be used solely to connect you with a physician in your area who uses the Aliya® PEF System. Please do not submit protected health information (PHI) — including diagnosis, treatment history, or medical records — through this form.
The Aliya® PEF System (K212871, K233884, and K253826) is 510(k) cleared in the United States for the surgical ablation of soft tissue. Galvanize Therapeutics® does not promote the off-label use of its products and nothing herein is intended to promote an off-label use of the Aliya PEF System. The Aliya PEF System is a tool for the surgical ablation of soft tissue it is not intended to treat, cure, prevent, nor mitigate any specific disease or condition.
For questions about coverage or eligibility for this procedure, please consult your physician and insurance provider.